Stocktoria
Travere Therapeutics, Inc. TVTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2003-07-23
Travere Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -12.8% | -138.9% | -267.2% | -292.2% | -151.3% |
| Net margin | -5.2% | -137.9% | -76.7% | -254.4% | -136.6% |
| FCF margin | — | — | -224.5% | -238.5% | -61.7% |
| Return on assets | -4.2% | -54.1% | -14.1% | -41.4% | -23.2% |
| Return on equity | -22.2% | -544.3% | -55.5% | -649.9% | -59.6% |
| Current ratio | 2.74 | 2.08 | 3.47 | 3.42 | 4.70 |
| Revenue growth | 110.5% | 60.5% | 32.7% | -17.0% | -33.5% |
Source: SEC EDGAR filings · CIK 0001438533 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.